Neuroone Medical Technologies is trading at $0.92, up 6.58%, after a peer-reviewed study of its OneRF trigeminal nerve ablation system reported favorable results.
- Announced October 29, the study found 14 of 15 patients immediately pain-free; all 15 had favorable outcomes at a mean six-month follow-up.
- The retrospective series was small; the authors said larger studies and longer follow-up are needed.